Dahmardeh Narjes, Asadi-Shekaari Majid, Arjmand Shokouh, Kalantaripour Tajpari, Basiri Mohsen, Shabani Mohammad
Intracellular Recording Lab, Kerman Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran; Department of Anatomical Sciences, Afzalipour Medical Faculty, Kerman University of Medical Sciences, Kerman, Iran.
Intracellular Recording Lab, Kerman Neuroscience Research Center, Neuropharmacology Institute, Kerman University of Medical Sciences, Kerman, Iran.
Neurosci Lett. 2017 Jul 13;653:376-381. doi: 10.1016/j.neulet.2017.06.015. Epub 2017 Jun 13.
Essential tremor (ET) is one of the most common movement disorders with unknown etiology. Despite lack of effective clinical treatments, some potential therapeutic factors and modulation of some neurotransmitters have been utilized to ameliorate motor symptoms in the animal models of tremor. In the current study, male Wistar rats (n=10 in each group) weighing 40-60g were divided into vehicle control groups (saline or DMSO), saline/DMSO+harmaline (30mg/kg, i.p.)+fingolimod (FTY720) (1mg/kg, i.p, 1h before harmaline injection) groups. Open field, rotarod, wire grip and foot print tests were used to evaluate motor function. The results demonstrated that administration of FTY720 can improve harmaline-induced tremor in rats. Moreover, FTY720 ameliorated gait disturbance. The results showed that FTY720 can recover step width, left and right step length; however, FTY720 failed to recover mobility duration. FTY720 also improved falling time and time spent in wire grip and rotarod, respectively. The current study provides the first evidence for the effectiveness of FTY720 on motor function in the harmaline model of ET. Furthermore, neuroprotective effects of FTY720 demonstrated in this study offer sphingosine-1-phosphate receptor (S1PR) modulators as a potential neuroprotective candidate against substance-induced tremor and a possible strategy for the treatment of patients with tremor.
特发性震颤(ET)是最常见的运动障碍之一,病因不明。尽管缺乏有效的临床治疗方法,但在震颤动物模型中,一些潜在的治疗因素和某些神经递质的调节已被用于改善运动症状。在本研究中,将体重40 - 60克的雄性Wistar大鼠(每组n = 10)分为溶剂对照组(生理盐水或二甲基亚砜)、生理盐水/二甲基亚砜+哈马灵(30毫克/千克,腹腔注射)+芬戈莫德(FTY720)(1毫克/千克,腹腔注射,在哈马灵注射前1小时)组。采用旷场试验、转棒试验、握力试验和足迹试验评估运动功能。结果表明,给予FTY720可改善大鼠哈马灵诱导的震颤。此外,FTY720改善了步态障碍。结果显示,FTY720可恢复步幅、左右步长;然而,FTY720未能恢复移动持续时间。FTY720还分别改善了跌落时间以及在握力试验和转棒试验中的停留时间。本研究首次提供了FTY720对ET哈马灵模型运动功能有效性的证据。此外,本研究中证明的FTY720的神经保护作用为1 - 磷酸鞘氨醇受体(S1PR)调节剂作为对抗物质诱导震颤的潜在神经保护候选药物以及治疗震颤患者的可能策略提供了依据。